

Htlv-Ii Infections

[View the current Htlv-Ii Infections InDepth page on BioPortfolio.com](#) ([PDF](#))

(http://www.bioportfolio.com/indepth/Htlv-Ii_Infections.html) - Regularly Updated.

Recent Publications on Htlv-Ii Infections:



- [Lookback study of HTLV-1 and 2 seropositive donors and their recipients in Belo Horizonte, Brazil.](#)
*The objective of this study was to perform lookback study in recipients of...*18th November, 2009
Fundacao Hemominas, Santa Efigenia, Brazil.- *Transfus Med.* 2009 Aug;19(4):180-8. ([DOI Direct Link](#))
- [Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.](#)
*BACKGROUND: Human T-lymphotropic virus (HTLV) type I is the causative...*29th September, 2009
Blood Systems Research Institute, San Francisco, CA, USA.- *Neurology.* 2009 Sep 8;73(10):781-9. ([DOI Direct Link](#))
- [High frequencies of functionally competent circulating Tax-specific CD8+ T cells in human T lymphotropic virus type 2 infection.](#)
*Human T lymphotropic virus type 2 (HTLV-2) is characterized by a...*19th September, 2009
Centre for Research in Infectious Diseases, University College Dublin,- *J Immunol.* 2009 Sep 1;183(5):2957-65. Epub 2009 Aug 5. ([DOI Direct Link](#))
- [Prevalence and risk factors for HIV, syphilis, hepatitis B, hepatitis C, and HTLV-I/II infection in low-income postpartum and pregnant women in Greater Metropolitan Vitoria, Espirito Santo State, Brazil.](#)
*Sexually transmitted infections during pregnancy pose a major risk to the...*27th August, 2009
Unidade de Referencia Ambulatorial para DST/AIDS, Serra, Brasil.- *Cad Saude Publica.* 2009 Mar;25(3):668-76.
- [Neurological aspects of HIV/human T lymphotropic virus coinfection.](#)
*Human T lymphotropic virus type 1 is associated with some neurologic...*6th August, 2009
Instituto de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz, Rio- *AIDS Rev.* 2009 Apr-Jun;11(2):71-8.
- [\[Prenatal screening for Trypanosoma cruzi and human T lymphotropic virus types 1 and 2 in pregnant Latin American women.\]](#)
*INTRODUCTION: To estimate the seroprevalence of infection by Trypanosoma...*1st August, 2009
Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital- *Enferm Infecc Microbiol Clin.* 2009 Mar;27(3):165-7. Epub 2009 Feb 11. ([DOI Direct Link](#))
- [Seroprevalence of HTLV-1/2 infection among native and immigrant pregnant women in Spain.](#)
*HTLV-1=2 antenatal screening is not mandatory in European countries. The...*29th July, 2009
Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio- *AIDS Res Hum Retroviruses.* 2009 Jun;25(6):551-4.
- [Retroviral infection in Peruvian men who have sex with men.](#)
*We tested 2655 Peruvian men who have sex with men for the presence of...*28th July, 2009

- Ministry of Health, Lima, Peru.- Clin Infect Dis. 2009 Jul 1;49(1):112-7. ([DOI Direct Link](#))
- [Comparison of signal-to-cutoff values in first, second, and third generation enzyme immunoassays for the diagnosis of HTLV-1/2 infection in "at-risk" individuals from Sao Paulo, Brazil.](#)
*Data obtained during routine diagnosis of human T-cell lymphotropic virus...*17th July, 2009
Immunology Department, Instituto Adolfo Lutz, Coordenadoria de Controle de- J Virol Methods. 2009 Aug;159(2):288-90. Epub 2009 Apr 5. ([DOI Direct Link](#))
 - [HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression.](#)
*Human T-cell lymphotropic viruses type 1 and 2 are retroviruses that share...*14th May, 2009
Virology Research Laboratory, Federal University of Bahia Hospital- AIDS Rev. 2009 Jan-Mar;11(1):8-16.
 - [Determinants of subject visit participation in a prospective cohort study of HTLV infection.](#)
*BACKGROUND: Understanding participation in a prospective study is crucial...*8th May, 2009
Department of Laboratory Medicine, University of California, San- BMC Med Res Methodol. 2009 Mar 10;9:19. ([DOI Direct Link](#))
 - [\[Prevalence of human T-cell lymphotropic virus \(HTLV-1/2\) infection among puerperae in Cuiaba, Mato Grosso, 2006\]](#)
*The prevalence of human T-cell lymphotropic virus (HTLV-1/2) infection...*7th May, 2009
Departamento de Ginecologia e Obstetricia, Universidade de Cuiaba, Cuiaba,- Rev Soc Bras Med Trop. 2009 Jan-Feb;42(1):28-32.
 - [Confirming the presence of HTLV-1 infection and the absence of HTLV-2 in blood donors from Arequipa, Peru.](#)
*Epidemiological studies conducted in Peru disclosed HTLV-1 to be prevalent...*5th May, 2009
Hospital Goyeneche, Arequipa, Peru.- Rev Inst Med Trop Sao Paulo. 2009 Jan-Feb;51(1):25-9.
 - [Human T-cell leukemia virus type 2 Rex carboxy terminus is an inhibitory/stability domain that regulates Rex functional activity and viral replication.](#)
*Human T-cell leukemia virus (HTLV) regulatory protein, Rex, functions to...*29th April, 2009
Center for Retrovirus Research, Department of Veterinary Biosciences, The- J Virol. 2009 May;83(10):5232-43. Epub 2009 Mar 11. ([DOI Direct Link](#))
 - [Molecular evidence of human T-cell lymphotropic virus types 1 and 2 \(HTLV-1 and HTLV-2\) infections in HTLV seroindeterminate individuals from Sao Paulo, Brazil.](#)
*BACKGROUND: Using enzyme immunoassays and Western blot (Wb) tests, HTLV...*14th April, 2009
Department of Infectious Diseases, University of Sao Paulo, Brazil.- J Clin Virol. 2009 Mar;44(3):185-9. Epub 2009 Feb 1. ([DOI Direct Link](#))

Htlv-ii Infections Patents:



- 7115590- [Phosphoramidate, and mono-, di-, and tri-phosphate esters of \(1R, cis\)-4-\(6-amino-9H-purin-9-yl\)-2-cyclopentene-1-methanol as antiviral agents](#)
- 5476765- [Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines](#)
- 5378805- [Immunoreactive HTLV-I/II ENV and POL peptides](#)
- 5359029- [Peptides and analogues and mixtures thereof for detecting antibodies to HTLV-I and HTLV-II viruses](#)
- 5234913- [Antiviral nucleoside combination](#)

- 5206435- [4-amino-2-cyclopentene-1-methanol](#)
- 5198539- [5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine](#)
- 5185437- [Therapeutic nucleosides](#)
- 5157114- [2',3'-dideoxy-3'-fluoro-5-ethynyluridine](#)
- 5153318- [3'-Azido nucleoside compound](#)
- 5089500- [Therapeutic nucleosides](#)
- 5087697- [Therapeutic nucleosides](#)
- 5068320- [2-amino-6-\(cyclopropylamino\)purine-9-.beta.-D-2',3'-dideo xyribofuranoside and its pharmaceutically acceptable salts](#)
- 5049671- [6-substituted purine carbocyclic nucleosides](#)
- 5547976- [Further indole derivatives with antiviral activity](#)
- 5663154- [2',3'-dideoxy-3'-fluoro-purine ribonucleosides](#)
- 5681696- [Synthetic peptide compositions with immunoreactivities to antibodies to HTLV](#)
- 6824977- [Assays for human T cell lymphotropic virus types I and II](#)
- 6686462- [Antiviral compounds and methods of administration](#)
- 6667387- [HCV core peptides](#)
- 6645501- [Anti-pathogen system and methods of use thereof](#)
- 6514979- [Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenase inhibitors and uses therefor](#)
- 6221355- [Anti-pathogen system and methods of use thereof](#)
- 6210903- [Peptide derived from human immunodeficiency virus type 1 \(HIV-1\), isolate Ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays](#)
- 6177435- [Therapeutic combinations](#)
- 6165730- [Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays](#)
- 6110662- [HTLV-I/HTLV-II assay and method](#)
- 6107288- [Antiviral nucleoside combination](#)
- 5891640- [Peptide derived from human immunodeficiency virus type 1 \(HIV-1\), isolate ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays](#)
- 5773211- [Differentiation of HTLV-I and HTLV-II using synthetic peptides](#)
- 5034394- [Therapeutic nucleosides](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

